[Special Stock] Encell Shows Strength on Asian Technology Transfer of Stem Cell Therapy
by Cha Minyoung
Published 10 Sep.2024 10:25(KST)
Updated 10 Sep.2024 10:32(KST)
![[Special Stock] Encell Shows Strength on Asian Technology Transfer of Stem Cell Therapy](http://www.asiae.co.kr/news/img_view.htm?img=2024072208164559128_1721603806.jpg)
Encell is showing strong performance following the news of the technology transfer of 'EN001 (mesenchymal stem cell therapy)' to six Asian countries.
As of 10:21 AM on the 10th, Encell is trading on the KOSDAQ market at 30,150 KRW, up 3,500 KRW (13.13%) from the previous close.
The current trading volume is 1.27 million shares, with a trading value of approximately 38.9 billion KRW.
Encell announced after the market closed on the 9th that it signed a contract to transfer the technology of the mesenchymal stem cell therapy EN001 to six Asian countries, including Hong Kong's Lucy Biotech. The contract consists of a signing fee of 19.5 million USD (25.4 billion KRW) and royalties, with an advance payment of 1.5 million USD (1.9956 billion KRW).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.